Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.

Kai QinKazuhito HonjoScott Sherrill-MixWeimin LiuRegina M StoltzAllisa K OmanLucinda A HallRan LiSarah SterrettEllen R FrederickJeffrey R LancasterMayur NarkhedeAmitkumar MehtaFoluso J OgunsileRima B PatelThomas J KetasVictor M Cruz PortilloAlbert CupoBenjamin M Larimer Paul A GoepfertPaul A GoepfertBeatrice H HahnRandall S Davis

Published in: PLoS medicine (2023)

CLL pathogenesis is characterized by a progressive loss of adaptive immune functions, including in most treatment-naïve patients, with preexisting memory being preserved longer than the capacity to mount responses to new antigens. In addition, higher NAb titers and response rates identify mRNA-1273 as a superior vaccine for CLL patients.

Keyphrases

chronic lymphocytic leukemia
sars cov
end stage renal disease
multiple sclerosis
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
binding protein
immune response
respiratory syndrome coronavirus
patient reported outcomes
advanced non small cell lung cancer
replacement therapy